Reduced Exercise Capacity, Chronotropic Incompetence, Inflammation and Symptoms in Post-Acute COVID-19

Durstenfeld et al. Cardiac Findings >12 months after COVID-19

Matthew S. Durstenfeld[1,2], Michael J. Peluso[1,3], Punita Kaveti[1,4], Christopher Hill[5], Danny Li[2], Erica Sander[4], Shreya Swaminathan[2], Victor M. Arechiga[2], Kaiwen Sun[1], Yifei Ma[2], Victor Zepeda[2], Scott Lu[3], Sarah A Goldberg[6], Rebecca Hoh[2], Sithu Win[1,2], J. Daniel Kelly[6,7,8], Timothy J. Henrich[9], Jeffrey N. Martin[6], Yoo Jin Lee[10], Mandar A. Aras[1,4], Carlin S. Long[1,4], Donald J. Grandis[1,4], Steven G. Deeks[1,3], Priscilla Y. Hsue[1,2]

1 Department of Medicine, University of California, San Francisco, CA, USA

2 Division of Cardiology, Zuckerberg San Francisco General, San Francisco, CA, USA

3 Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA

4 Division of Cardiology, UCSF Health

5 School of Medicine, University of California, San Francisco, USA

6 Department of Epidemiology and Biostatistics, University of California, San Francisco, USA

7 Institute of Global Health Sciences, University of California, San Francisco, USA

8 F.I. Proctor Foundation, University of California, San Francisco, USA

9 Division of Experimental Medicine, University of California, San Francisco, USA

10 Cardiac and Pulmonary Imaging, Department of Radiology, University of California, San Francisco

Presented in part as a late breaking oral presentation at the Conference on Retroviruses and Opportunistic Infections, February 15, 2022 and as an oral presentation at the Heart Rhythm Society 2022 on May 1, 2022

Address for Correspondence & Reprints:

Matthew S. Durstenfeld, MD

Division of Cardiology, UCSF at Zuckerberg San Francisco General Hospital

1001 Potrero Avenue, 5G8

San Francisco, CA 94110, USA

Tel: +1 628 206 5562; Fax: +1 628 206 5447

e-mail: matthew.durstenfeld@ucsf.edu twitter: @durstenfeld

Word Count: 5310

Abstract

BACKGROUND Mechanisms underlying persistent cardiopulmonary symptoms following SARS-CoV-2 infection (post-acute sequelae of COVID-19 “PASC” or “Long COVID”) remain unclear. The purpose of this study was to elucidate the pathophysiology of cardiopulmonary PASC using multimodality cardiovascular imaging including cardiopulmonary exercise testing (CPET), cardiac magnetic resonance imaging (CMR) and ambulatory rhythm monitoring.

METHODS In the Long-Term Impact of Infection with Novel Coronavirus (LIINC) Cohort, we performed CMR, CPET, and ambulatory rhythm monitoring among adults > 1 year after PCR-confirmed SARS-CoV-2 infection. We used logistic and linear regression to compare those with and without cardiopulmonary symptoms (dyspnea, chest pain, palpitations) adjusting for confounders.

RESULTS One hundred twenty individuals were studied, among whom 46 participants (unselected for symptom status) had at least one advanced test performed at median 17 months (IQR 15-18). Median age was 52 (IQR 42-61), 18 (39%) were female, and 6 (13%) were hospitalized for severe acute infection. On CMR (n=39), smaller RV volume and stroke volume and higher extracellular volume were present among those with symptoms, but no evidence of late-gadolinium enhancement or differences in T1 or T2 mapping were demonstrated. We did not find arrhythmias on ambulatory monitoring. In contrast, on CPET (n=39), 13/15 (87%) participants with reduced exercise capacity (<85% predicted) reported cardiopulmonary symptoms or fatigue (p=0.008). Adjusted peak VO_2 was 2.7 ml/kg/min lower among those with cardiopulmonary symptoms (95%CI -6.9 to 1.5; p=0.20) or -11% predicted (95%CI -27 to 5, p=0.17). Including fatigue along with cardiopulmonary symptoms, the adjusted difference in peak VO_2 was -5.9 ml/kg/min (-9.6 to -2.3; p=0.002) or -21% predicted (-35 to -7; p=0.006).

Chronotropic incompetence was the primary abnormality among 9/15 with reduced peak VO_2. Adjusted heart rate reserve <80% was associated with reduced exercise capacity (OR 15.6, 95%CI 1.30-187; p=0.03). Those with chronotropic incompetence had higher hsCRP, lower heart rate recovery, and lower heart rate variability suggestive of autonomic dysfunction.

CONCLUSIONS Reduced exercise capacity and reduced heart rate response to exercise, and hsCRP are associated with persistent cardiopulmonary symptoms more than 1 year following COVID-19. Chronic inflammation and autonomic dysfunction may underlie cardiopulmonary PASC.

Key Words

SARS-CoV-2; COVID-19; post-acute sequelae of COVID-19 (PASC); "Long COVID"; chronotropic incompetence; cardiopulmonary exercise testing (CPET); cardiac magnetic resonance imaging (CMR); ambulatory rhythm monitoring

Abbreviations list: PASC (post-acute sequelae of COVID-19); hsCRP=high sensitivity c reactive protein; LIINC=Long-term Impact of Infection with Novel Coronavirus; LV=left ventricle; RV=right ventricle; cardiopulmonary exercise testing (CPET); cardiac magnetic resonance imaging (CMR); adjusted heart rate reserve (AHRR); premature atrial contraction (PAC); premature ventricular contraction (PVC); supraventricular tachycardia (SVT) POTS=postural orthostatic tachycardia syndrome;

Clinical Perspective

What is New?

- Impaired chronotropic response to exercise is associated with reduced exercise capacity and cardiopulmonary symptoms more than 1 year after SARS-CoV-2 infection.
- Findings on ambulatory rhythm monitoring point to perturbed autonomic function, while cardiac MRI

  findings argue against myocardial dysfunction and myocarditis.

Clinical Implications:

- Cardiopulmonary testing to identify etiologies of persistent symptoms in post-acute sequalae of COVID-19 or “Long COVID” should be performed in a manner that allows for assessment of heart rate response to exercise.
- Therapeutic trials of antiviral, anti-inflammatory, and exercise strategies in PASC are urgently needed and should include assessment of symptoms and objective testing with cardiopulmonary exercise testing.

Introduction

Following acute SARS-CoV-2 infection, some individuals suffer from persistent symptoms called "Long COVID" or post-acute sequelae of COVID-19 (PASC). Although some studies estimate that >30% of individuals experience persistent symptoms after SARS-CoV-2 infection,[1-3] population-based estimates range from 3-12%.[4] Understanding PASC represents a major public health issue given that more than half the US population has been infected.[5]

Mechanisms of PASC remain poorly understood, but chronic inflammation, aberrant immune activation, and endothelial dysfunction have been implicated.[6] Characterizing phenotypes of cardiopulmonary PASC with multi-modality cardiac testing may yield insights into potential mechanisms. We previously demonstrated that inflammatory markers and possibly pericardial effusions were associated with symptoms 6 months following SARS-CoV-2 infection.[7] We and others have demonstrated normal echocardiographic cardiac function 3-6 months after COVID-19, suggesting that other techniques are needed to identify mechanisms of symptoms.[7-12] Evaluation with cardiac magnetic resonance imaging (CMR) has also confirmed normal cardiac function and revealed changes in parametric mapping and late gadolinium enhancement but without clear associations with symptoms or consistent differences from controls.[13-17] Studies using cardiopulmonary exercise testing (CPET) have consistently demonstrated reduced exercise capacity at 3-6 months after SARS-CoV-2 infection with mixed results regarding classification of the etiology of exercise limitation.[17-21] Finally, to our knowledge, whether arrhythmias explain palpitations in PASC is unknown beyond 3 months.[22, 23]

The Long-Term Impact of Infection with Novel Coronavirus (LIINC) study (NCT 04362150) was implemented to study COVID-19 recovery in individuals with confirmed SARS-COV-2 and includes individuals with asymptomatic to severe acute disease.[24] The purpose of this study was

to elucidate mechanisms of cardiopulmonary symptoms more than 1 year following SARS-CoV-2 infection by comparing symptomatic and recovered individuals using a multi-modality tests including blood-based markers, echocardiography, cardiac magnetic resonance imaging, cardiopulmonary exercise testing, and ambulatory rhythm monitoring.

Methods

As previously reported, the Long-term Impact of Infection with Novel Coronavirus (LIINC) study is a COVID recovery cohort that includes longitudinal symptom assessment.[24] In a subset, we measured biomarkers and performed echocardiograms which we have previously reported.[7] Here we report findings from the subset who have undergone additional cross-sectional cardiopulmonary testing including CPET, CMR, and ambulatory rhythm monitoring.

Participants

Participants were included if they had PCR-confirmed SARS-CoV-2 infection, enrolled in LIINC, and agreed to participate in additional cardiopulmonary testing. We invited participants who met the inclusion and exclusion criteria who had completed the echocardiogram study visit in order of date of infection (earliest first) irrespective of symptom status. Participants were excluded who were pregnant (to reduce confounding due to expected changes during pregnancy) or had significant cardiopulmonary disease including congenital heart disease, heart failure, myocardial infarction, or heart surgery. Additionally, those with non-MRI compatible implants or claustrophobia were excluded from CMR; those with estimated GFR <30ml/min/1.73m^2 were excluded from receiving gadolinium contrast. Those unable to exercise on cycle ergometer were excluded from CPET. Demographics including gender, race, ethnicity, income, and education were self-reported by participants.

Symptoms

Individuals were queried regarding 32 symptoms from the Centers for Disease Control list and from the Patient Health Questionnaire Somatic Symptom Scale.[24] At enrollment, participants completed a structured interview about medical history, characteristics of acute infection, cardiopulmonary diagnoses, and symptoms within the previous two weeks, which were considered COVID-19-related only if new or worsened since infection. We systematically asked about fatigue, shortness of breath, chest pain, palpitations, syncope, edema, and positional symptoms.

Echocardiography

A cardiac sonographer performed echocardiograms with a GE VIVID E90 machine at the first study visit using a standardized protocol. Post-processing and measurements were performed by a single echocardiographer using GE EchoPAC software according to ASE guidelines, as we have previously described.[7]

Blood-Based Measures

Participants had venous blood collected and processed for serum and plasma on the day of the echocardiogram. Samples were batch processed for measurement of high sensitivity c-reactive protein (hs-CRP; ADVIA® Chemistry CardioPhase™ High Sensitivity C-Reactive Protein assay). Samples were assayed blinded with respect to patient and clinical information, and assay performance was consistent with the manufacturer's specifications. Additionally, immediately prior to the CMR, blood was drawn for measurement of hematocrit for calculation of extracellular volume.

Cardiac Magnetic Resonance Imaging

Multiparametric, sequence-standardized, blinded (technician and reader) cardiac magnetic resonance imaging (CMR) was performed at UCSF China Basin with a 3 Tesla system (Premier, General Electric). The CMR protocol consisted of acquisition of the following sequences after multiplane localizers prior to gadolinium injection: fast imaging employing steady state acquisition (FIESTA) cine in the axial short axis planes, pre-contrast T1 mapping sequences using MOLLI 5-(3)-3 technique, as well as pre-contrast T2 mapping at the basal, mid, and apical short axis planes and T2 fat-saturated weighted black blood spin-echo images in the short axis plane. 8-10 minutes after intravenous gadolinium injection, phase sensitive inversion recovery (PSIR) late gadolinium enhancement imaging in short axis full stack, 4 chamber full stack, three slices of 2 chamber images, and post-contrast T1 mapping sequences were obtained. Inversion times were individualized to null the myocardium. MRI measurements were performed by a single reader at a dedicated workstation using Medis (Leiden, Netherlands) and AI assisted Arterys (San Francisco, CA) software under supervision of a senior cardiac imager, both blinded to all clinical variables, and in accordance with Society for Cardiovascular Magnetic Resonance task force recommendations. Artey software was used for T1 and T2 mapping and ECV calculation using pre- and post-contrast MOLLI sequences.

Cardiopulmonary Exercise Testing

Cardiopulmonary exercise tests were performed by an experienced exercise physiologist and noninvasive cardiology nurse practitioner blinded to participant data according to standard protocol using a metabolic cart (Medical Graphics Corporation Ultima CardiO_2) and supine cycle ergometer (Lode Corival CPET) with continuous 12 lead ECG monitoring (GE CASE) and noninvasive blood pressure and pulse oximetry measurement. First, baseline ECG, blood pressure, and rest spirometry including maximum voluntary ventilation (MVV) were measured.

We determined the rate of work increase per 1 minute step based on the expected peak VO_2 from the MVV for a goal 10 minute test, rounded up or down to the nearest 5 Watts/min based on reported exercise (range 10-30W/min). Participants underwent a 2-minute rest phase, 2-minute no resistance warm up, and then 1-minute steps. Breath-by-breath oxygen consumption (VO_2) and carbon dioxide production (VCO_2) were measured continuously with best 5/7 averaging. Participants were blinded to time, wattage, and peak VO_2 during the test. Participants were encouraged to exercise to their maximum ability, with the test stopped prematurely for severe hypertension, relative hypotension, moderate to severe angina, ventricular tachycardia or couplets, ST elevations or ST depressions >2 mm. Reason for stopping was recorded. Exercise effort quality was assessed by Borg Scale and by the respiratory exchange ratio (RER); tests with RER <1.05 were excluded from analysis. Anaerobic threshold was determined manually by the exercise physiologist using the slope method. CPETs were interpreted separately by two independent readers and differences in interpretation were discussed and resolved through consensus.

For CPET analyses, we evaluated measured peak VO_2 (in ml/kg/min) and used the Wasserman equations to estimate the percent predicted VO_2 for sedentary adults achieved.[25-27] We classified participants as having reduced exercise capacity if observed exercise capacity was <85% predicted. We considered ventilatory limitation if rest spirometry was abnormal, tidal volume did not double over baseline reaching at least 50% of FVC, breathing reserve did not reach < 30%, VD/VT was greater than 0.2 with exercise, or desaturation occurred during exercise. We classified participants as having a cardiac limitation if there were ischemic ECG changes, oxygen pulse was reduced and plateaued early, AT occurred at less than 40% of predicted maximal VO_2, and if ventilatory efficiency slope (VE/VCO_2) was <32. We defined an abnormal chronotropic

response to exercise as achieving <80% of the adjusted heart rate reserve (AHRR) calculated as $(HR_{peak}-HR_{rest})/(220\text{-age}-HR_{rest})$; as a sensitivity analysis, achieving <85% of the age predicted heart rate (220-age) was also used.[28] We considered exercise limitation to be likely due to deconditioning, obesity or impaired gas exchange if the exercise capacity was reduced and there was no cardiac or ventilatory limitation.

Ambulatory Rhythm Monitoring

After completion of CMR (or CPET if excluded from CMR), an ambulatory rhythm monitor (Carnation Ambulatory Monitor, BardyDx) was placed on the chest. Participants were instructed to press the button for any cardiopulmonary symptoms and record symptoms in a diary. Participants were instructed to remove the device after 2 weeks if it had not spontaneously fallen off and mail it back for processing with the symptom diary. Monitors were processed according to BardyDx standard operating procedures and reports were reviewed and overread by a cardiologist.

Statistical Design

As we have previously reported, we defined a composite symptom variable for cardiopulmonary PASC including chest pain, dyspnea, or palpitations in the preceding 2 weeks prior to the study visit;[7] all participants had new symptoms, were more than 3 months after SARS-CoV-2 infection, and did not have alternative cardiac disease to explain their symptoms, consistent with the WHO definition of PASC. We also considered self-reported exercise limitation, reduced exercise capacity <85% predicted, and chronotropic incompetence defined as reduced exercise capacity <85% predicted and AHRR<80%.[28] Adjusted models are adjusted for potential confounders including age, sex, time since SARS-CoV-2 infection, hospitalization for acute

SARS-CoV-2 infection, and body mass index. We used linear regression to estimate adjusted differences between those with and without symptoms in quantitative parameters and logistic regression to estimate the association with symptoms based on differences in quantitative parameters. For count outcomes (number of button pushes on rhythm monitoring), we used Poisson regression. Non-normally distributed variables (hsCRP, T1 mapping times, premature atrial contraction burden, for example) were log-transformed and findings are reported per doubling or per 10-fold change depending on the range of values. We conducted sensitivity analyses considering other definitions of symptoms and additionally adjusting for potentially relevant past medical history and echocardiographic parameters. We also conducted additional sensitivity analyses to better understand the association between HR and peak VO_2 as detailed in the supplemental materials.

The study was approved by the UCSF Committee on Human Research (IRB 20-33000) and all participants provided written informed consent. REDCap was used for data entry. Statistical analyses were performed using STATA version 17.1 and additional visualization was done using R version 4.2.0 using the ggplot2 package.

RESULTS

Participant Characteristics

Among 120 participants, median age was 53 (IQR 42-61), 45 (38%) were female, and 29 participants (24%) had severe acute infection requiring hospitalization. Other demographics and past medical history are shown in Table 1. Among 46 participants who had at least one advanced test performed, median age was 52 (IQR 42-61), 18 (39%) were female, and 6 (13%) were hospitalized (2 in ICU). The only notable difference between the subset who underwent

advanced testing was earlier date of infection ($p<0.001$; Supplemental Table 1). All had received at least one COVID vaccine prior to advanced testing.

Symptoms Persist at 18 Months

At visit 1, 56/120 (47%) reported cardiopulmonary symptoms at a median 6 months after SARS-CoV-2 infection. At visit 2, 19/46 (41%) reported cardiopulmonary symptoms at a median 17.0 months. Specifically, 14 continued to have symptoms, 9 people had recovered and 5 people developed new symptoms. Individual symptom patterns were similar (Supplemental Table 2). Reporting reduced exercise capacity at the second visit was strongly associated with reporting other cardiopulmonary symptoms (OR 8.04, 95%CI 1.94-33.3; $p=0.004$); 78% of our sample who reported reduced exercise capacity reported other cardiopulmonary symptoms compared to 32% who reported preserved or improved exercise capacity ($p=0.003$).

Reduced Exercise Capacity on CPET

Out of 40 participants who attended a CPET visit, 39 completed CPET at a median 17.5 months (IQR 15.5-18.4) after SARS-CoV-2 infection (one excluded due to hypertensive urgency). No participants were taking beta blockers, non-dihydropyridine calcium channel blockers, or ivabradine at the time of CPET. Two tests (one with and one without symptoms) were stopped early for hypertensive response after predicted normal heart rate and exercise capacity were reached but before the participants felt they needed to stop. All other tests were completed to maximal exertion, and all tests had a respiratory exchange ratio (RER) >1.05 with no difference in RER achieved by symptom status.

Overall, 15/39 (38%) participants had reduced exercise capacity (peak VO_2 <85% predicted). Among those with reduced exercise capacity, 9/15 (60%) reported chest pain, dyspnea, or

palpitations and 13/15 (87%) reported cardiopulmonary symptoms or fatigue. The odds of reduced exercise capacity were 3.0 times higher among those reporting cardiopulmonary symptoms (95%CI 0.8-11.4; p=0.11) and 9.1 times higher among those reporting cardiopulmonary symptoms or fatigue (95%CI 1.7 to 49.6; p=0.01). As shown in Figure 1, exercise capacity was reduced among those with cardiopulmonary symptoms, although it was not statistically significant. After adjustment, peak VO_2 was 2.7 ml/kg/min lower among those reporting chest pain, dyspnea, or palpitations (95%CI -6.9 to 1.5; p=0.20) or -11% predicted (95%CI -27 to 5, p=0.17). The adjusted difference was -5.9 ml/kg/min among those with chest pain, dyspnea, palpitations, or fatigue (-9.6 to -2.3; p=0.002) or -21% (-35 to -7; p=0.006). Other ways of considering symptoms are shown in Supplemental Table 2.

Classification of Reduced Exercise Capacity by Pattern of CPET Findings

Most CPET parameters were not significantly different among those with and without symptoms (Table 2), except anaerobic threshold. Anaerobic threshold occurred early (at a lower % predicted maximum VO_2) among those with symptoms, and the odds of symptoms were 2.1-fold higher per 5% decrease in anaerobic threshold relative to predicted peak VO_2 (95%CI 1.08 to 4.20; p=0.03). There were no significant differences on rest echocardiography (Supplemental Table 3) or spirometry (Supplemental Table 4) or associations between these parameters and peak VO_2 (results not shown).

In classifying the etiology of reduced exercise capacity, no participants had a pattern consistent with a ventilatory limitation (and none with desaturation), one participant had a cardiac limitation (reduced oxygen pulse pressure and ischemic changes on ECG), one participant's peak VO_2 was slightly below 85% predicted with no other abnormalities, and three participants had findings most consistent with deconditioning/obesity or impaired gas exchange. Among

participants with reduced exercise capacity (<85% predicted), 9/15 (56%) had chronotropic incompetence with an adjusted heart rate reserve (AHRR) <80% and peak heart rate <85% age predicted maximum. One participant with obesity and deconditioning had AHRR<80% but APMHR=85%, and we did not classify that participant as having chronotropic incompetence.

Chronotropic Incompetence on CPET

Nineteen participants had an AHRR<80%, which was associated with lower peak VO_2 (Figure 2). We classified participants into three categories of heart rate response to exercise by whether they reached 85% predicted maximum VO_2 and 80% AHRR (Figure 3 and Supplemental Figure 1). Not reaching AHRR >80% during CPET was associated with 15.6x higher odds of having reduced exercise capacity <85% predicted (95%CI 1.30-187; p=0.03) and 4.9 ml/kg/min lower peak VO_2 (95CI CI -9.3 to -0.5; p=0.03). Participants with chronotropic incompetence (peak VO_2 <85% predicted, AHRR <80%, and considered the primary explanation for reduced exercise capacity, n=9) had lower peak heart rate and lower AHRR achieved (Table 5, p<0.0001 for all). Chronotropic incompetence was associated with 6.4 ml/kg/min lower peak VO_2 (95%CI -11.3 to -1.6; p=0.01), a large and clinically significant difference. Heart rate recovery at 1 minute after cessation of exercise was also reduced among those with chronotropic incompetence. Respiratory exchange ratio, a measure of reaching peak exercise capacity, was not significantly lower among those with chronotropic incompetence (difference 0.04, 95%CI -0.02 to 12; p=0.19). We conducted additional sensitivity analyses to exclude the possibility that observed differences in heart rate were not explained by differences in achieved VO_2 (Supplemental Results and Figures).

Normal Cardiac Structure and Function on CMR

One participant was not administered gadolinium due to eGFR<30, and 3 participants could not complete the protocol due to claustrophobia. CMR demonstrated normal LV and RV volumes and ejection fraction in all participants (n=39, Table 4). There were statistically significant associations between smaller RV end diastolic volume index and smaller stroke volume and symptoms. No participants had late gadolinium enhancement suggestive of myocardial scar. Other markers suggestive of cardiac inflammation including native T1 and T2 parametric mapping values and calculated extracellular volume were not significantly different by symptom status or associated with symptoms. A high proportion of participants (11/39, 28%) had trace or small pericardial effusions with no difference by symptom status.

Those with chronotropic incompetence had 19ml lower stroke volume at rest (95%CI 3-34; p=0.02). Those with chronotropic incompetence also had higher extracellular volume (+6.2%, 95%CI 0.7 to 11.7; p=0.03).

No Arrythmias on Ambulatory Rhythm Monitoring

There were no clinically significant arrhythmias including atrial fibrillation or atrial flutter noted on ambulatory rhythm monitoring among those with or without symptoms (Table 5). There were no statistically significant differences in premature atrial contractions (PAC), premature ventricular contractions (PVC), or supraventricular tachycardias (SVT) by symptom status. After adjustment, cardiopulmonary symptoms were not associated with an increased burden of PAC, PVC, or supraventricular tachycardia episodes. We could not exclude meaningful increases in PVC burden given wide confidence intervals since most participants had no PVCs. Average HR and HR variability as measured by standard deviation n to n (SDNN) were lower, but not statistically significantly different between those with and without symptoms. Results were similar after adjusting for echocardiographic and CMR parameters including LVEF, LV strain,

and LA volume index. Button pushes correlated with brief episodes of SVT in one participant with PASC, but most button pushes were associated with sinus rhythm, sinus tachycardia, or supraventricular ectopy (Supplemental Figure 5).

Ambulatory Rhythm Monitoring Findings among those with Chronotropic Incompetence on CPET

Peak heart rate on CPET was significantly positively correlated with maximum sinus heart rate on ambulatory rhythm monitoring (Pearson's r=0.73; p<0.001). Those with chronotropic incompetence had a higher average heart rate on ambulatory rhythm monitoring, higher minimum heart rate, lower maximum heart rate, and lower heart rate variablility (Table 5). No individuals had 2nd or 3rd degree heart block or evidence of sinus node dysfunction on ambulatory rhythm monitoring. PR intervals were not significantly longer among those with chronotropic incompetence (174ms vs 162ms, +12ms, 95%CI -4 to +27; p=0.13).

Increased hsCRP is Associated with Reduced Exercise Capacity and Pericardial Effusions

After adjustment, the odds of symptoms at the second visit were 1.36 times higher per doubling of hsCRP measured approximately 1 year prior (0.70-2.64; p=0.36), which was not statistically significant. Per each doubling of hsCRP, peak VO_2 was 1.8 ml/kg/min lower (95%CI 0.2 to 3.3; p=0.03) or -6.3% predicted (95%CI 0.6 to 12; p=0.03). hsCRP was not statistically significantly associated with chronotropic incompetence (OR 1.15, 95%CI 0.43-3.1; p=0.78) or AHRR (-2.5% per doubling, 95%CI -9 to 4; p=0.44). Lastly, the odds of having a pericardial effusion on CMR were 1.8 times per doubling of hsCRP (95%CI 1.09-2.92; p=0.02).

Discussion

We demonstrate that reductions in objective metabolic capacity during exercise as assessed by CPET are present among individuals with cardiopulmonary symptoms at 18 months following acute SARS-CoV-2 infection. Peak oxygen consumption was lower among those with cardiopulmonary symptoms, especially when defined to include fatigue. Reduced exercise capacity among those recovering from COVID-19 was strongly associated with a blunted heart rate response to exercise, and our findings suggest that chronotropic incompetence is a likely mechanism of reduced exercise capacity for some individuals with PASC. Additionally, we found that chronotropic incompetence on CPET was associated with ambulatory rhythm findings that suggest autonomic dysfunction including changes in heart rate and heart rate variability. Reduced VO_2 was also associated with elevated hsCRP. Other than pericardial effusions (also associated with elevated hsCRP), we did not find evidence of persistent cardiac inflammation or dysfunction on echocardiography or cardiac MRI, and also no evidence of arrhythmias on ambulatory rhythm monitoring. Furthermore, our study exemplifies the value in assessing disease mechanisms through a comprehensive evaluation of cardiac imaging (echo, CMR), cardiopulmonary exercise testing, and rhythm evaluation in the setting of individuals with and without symptoms 18 months after acute COVID-19 infection.

Other Studies of PASC using CPET

To date, six studies have compared symptomatic and recovered individuals at 3-6 months after COVID. All reported lower peak VO_2 among those with symptoms despite differences in defining symptoms.[18-21, 29, 30] Most assessed mostly previously hospitalized individuals at 3-6 months after infection. These studies have not reached consistent conclusions regarding the etiology of reduced exercise capacity, which may be related to different study populations, exercise protocols and proportions with sub-maximal tests. Two studies attributed lower peak

VO_2 to inadequate augmentation of stroke volume[30] or chronotropic incompetence and poor stroke volume augmentation.[21] Others have attributed exercise limitations to ventilatory inefficiency from pulmonary vasculopathy,[18] respiratory abnormalities,[19] obesity and differences in cardiorespiratory fitness[29] and deconditioning.[20, 21]

Impaired oxygen extraction at the peripheral level (assessed using invasive CPET) has also been suggested to explain reduced exercise capacity among those with PASC at 11 months after infection by Singh et al.[31] However, they describe stopping CPETs once RER was greater than 1.10 or heart rate was >85% predicted, which is below maximal exercise for most individuals and does not allow evaluation of chronotropic incompetence. They hypothesize that autonomic regulation of microcirculatory function may be one mechanism by which SARS-CoV-2 may alter oxygen extraction during exercise.[32] Others have hypothesized that IL-6 (which may be elevated in PASC)[33] functions as a myokine that regulates energy allocation during exercise.[34] We did not find differences in the VO_2 work slope, a noninvasive correlate of peripheral oxygen extraction, but we did not measure peripheral oxygen extraction since we did not perform invasive CPET. Mancini et al and others have found that dysfunctional (rapid, erratic) breathing or exercise hyperventilation may contribute to symptoms of persistent dyspnea in PASC.[35-37] In contrast, we did not observe dysfunctional breathing in any participant.

Although not a universal finding, several other groups have also reported chronotropic incompetence in PASC. Szekely et al found that 75% of PASC participants had chronotropic incompetence compared to 8% of control participants; they reported that chronotropic incompetence was the most likely explanation of reduced exercise capacity in PASC.[21] They also found reduced stroke volume augmentation consistent with Brown et al[30] and higher peripheral oxygen extraction consistent with Singh et al.[21, 31] Abdallah et al found that chronotropic

incompetence, present in 38% of their sample, contributed to exercise limitation, with greater limitations in exercise and heart rate among hospitalized individuals.[38] Jimeno-Almazán et al found chronotropic incompetence on CPET using a cycle ergometer and confirmed by treadmill testing among 4/32 individuals (13% of study sample) with reduced exercise capacity after COVID-19.[39] Ladlow et al found that dysautonomia as defined by heart rate parameters (resting HR>75, HR increase <89 bpm, and HR recovery at 1 minute <25 bpm)[40] was associated with lower peak VO_2 among individuals with PASC.[41] Our findings build upon these earlier studies by demonstrating chronotropic incompetence at 18 months following COVID-19 and also including evaluation of cardiac inflammation, structural heart disease and cardiovascular arrhythmias in study participants along with including recovered individuals as a comparator group and adjusting for confounders in our models.

Clinical Significance of Findings: Chronotropic Incompetence, Outcomes and Associated Findings of Vascular Dysfunction

Higher resting heart rate and blunted heart rate response during exercise testing are associated with development of cardiovascular disease, sudden death, and all-cause mortality among men without known coronary artery disease.[40, 42, 43] Chronotropic incompetence is also associated with impaired endothelial function assessed by brachial flow-mediated vasodilation[44] and abnormal endothelial function has been demonstrated to be present in the setting of early PASC.[45, 46] Abnormal endothelial function assessed with non-invasive brachial artery flow-mediated dilation may be associated with reduced VO_2 in PASC.[47] Coronary microvascular dysfunction, present in some people recovering from COVID-19,[48] is also associated with chronotropic incompetence in the general population with microvascular dysfunction.[49, 50]

Autonomic Function in PASC

Consistent with Ladlow et al's findings, altered autonomic function is the most likely unifying explanation for the constellation of findings observed in our study.[41] Alterations in autonomic function could explain chronotropic incompetence, blunted heart rate recovery, and reduction in heart rate variability. Perturbed autonomic function may also explain altered peripheral oxygen extraction, preload failure, and disordered breathing. SARS-CoV-2 may lead to damage or dysfunction of the peripheral autonomic nerve fibers as sequalae of direct viral infection, secondary inflammation of the nerves, or an autoimmune neuropathy. Two groups have found evidence of a small fiber neuropathy among those with COVID-19 associated with abnormal autonomic testing.[51, 52]

Autonomic dysfunction could also occur via direct infection of autonomic regulatory regions of the brainstem tone, which are anatomically close to the cribiform plate and the olfactory nerves. A meta-analysis of autopsy studies of individuals who died from COVID-19 demonstrated that brainstem abnormalities were commonly reported, with detection of viral RNA and proteins.[53] Our group has previously demonstrated abnormal markers of neurologic injury are present in serum[54] and CSF.[55]

Chronic inflammation in other conditions is associated with an imbalance between parasympathetic and sympathetic activation and changes in heart rate variability.[56, 57] Young adults recovering from SARS-CoV-2 have elevated sympathetic activation at rest compared to healthy controls.[58] Consistent with our findings that elevated hsCRP is associated with reduced exercise capacity, one other group found that hsCRP, IL-6, and TNF-alpha are associated with reduced peak VO2 3 months after hospitalization for COVID-19.[59] Elevated inflammatory markers are associated with reduced exercise capacity and chronotropic incompetence among adolescents and adults with obesity.[44, 60] In heart failure, resting heart rate is positively associated

with levels of hsCRP, but chronotropic incompetence during exercise is negatively correlated with copeptin (C-terminal portion of arginine) and norepinephrine levels.[61] Inflammation in the setting of stress (as evidenced in the association between amygdalar activity and bone-marrow/arterial inflammation)[62] has also been implicated in the pathophysiology of health disparities[63, 64] and post-traumatic stress disorder.[65] Vascular inflammation has been reported in early PASC.[66] Thus, inflammatory responses to stress from direct viral infection, chronic immune activation, or from the distressing nature of persistent symptoms could potentially alter the ability to augment heart rate during exercise in PASC even without direct damage to the autonomic nervous system or the heart.

Alternative Possibility: SARS-CoV-2 Alters Sinus Node Function

Sinus node remodeling has been hypothesized to reduce sinus node reserve among patients with heart failure.[67] Apart from autonomic function, SARS-CoV-2 may directly affect sinus node function. Han et al elegantly demonstrated that SARS-CoV-2 can infect the sinoatrial node in hamsters and human embryonic stem cell-derived sinoatrial-like pacemaker cells resulting in sinoatrial node-dysfunction including changes in calcium handling, activated inflammatory pathways, and induced ferroptosis.[68] Although we did not find evidence of localized or diffuse fibrosis on cardiac MRI or evidence of sinus node dysfunction on ambulatory rhythm monitoring or ECG monitoring during CPET (ie sinus pauses, Wenckebach, blocked PACs), sinus node dysfunction could explain chronotropic incompetence.

Role of Deconditioning in PASC

Multiple case series have reported that deconditioning is the primary cause of exercise limitation in PASC.[20, 69-72] Our findings argue against deconditioning as the primary explanation as the

majority of individuals had normal oxygen pulse and normal VO_2 to work slope which suggest normal augmentation of cardiac output. We found earlier anaerobic thresholds which can be seen in deconditioning and identified three individuals (8% of sample, 20% with reduced exercise capacity) whose pattern of findings is most consistent with deconditioning, obesity, or alterations in peripheral oxygen utilization. Our findings of smaller LV and RV volumes could be consistent with deconditioning, although we did not find a lower LV mass index among those with symptoms or reduced exercise capacity (possibly confounded by pre-existing hypertension). One of the challenges with identifying deconditioning as a cause is that it is also a natural effect of reduced exercise, such that those with symptoms limiting exercise capacity will be expected to have deconditioning.

CMR and Ambulatory Rhythm Monitoring Findings

Consistent with other studies that used CMR to look for structural damage, our study reassuringly did not find evidence of abnormal cardiac function or late gadolinium enhancement suggestive of scar. Our findings extend those of Joy et al and Cassar et al from 6 months after infection by demonstrating that over approximately 18 months after infection there remains no evidence for significant scar.[14, 17] Neither study found differences in late gadolinium enhancement or parametric mapping compared to controls at 6 months suggestive of myocardial scar or ongoing inflammation.

Our study also extends three prior studies examining arrhythmias after COVID-19 at 3 months using ambulatory monitoring. Ingul et al found that having more than 200 PVCs in 24 hours was common 3 months after hospitalization, but they did not adjust for cardiac comorbidities.[22] Dewland et al demonstrated no significant arrhythmias nor increased burden of ectopy on 2 week ambulatory rhythm monitoring among outpatients at 3 months.[23] Another study estimated that

the prevalence of inappropriate sinus tachycardia is 20% among individuals with PASC; we only identified one individual (without cardiopulmonary symptoms) with resting sinus heart rate >=100 bpm and average sinus rate >90 bpm on ambulatory monitoring.[73] Nonetheless, our findings regarding heart rate variability among those with chronotropic incompetence are consistent with theirs regarding heart rate variability. Our findings suggest that arrhythmias or inappropriate sinus tachycardia are unlikely to explain symptoms among those with PASC more than 1 year after infection.

Implications for Therapy

Investigation into mechanisms of PASC may benefit from proof-of-concept approaches to identify potential targets for intervention. Given associations with elevated inflammatory markers, targeting inflammatory or anti-viral pathways are intriguing possibilities worthy of investigation, although whether such interventions can restore autonomic nervous system function remains unknown. In those without cardiac implantable devices, exercise is the only intervention demonstrated to improve chronotropic response to exercise and improve peak VO_2 among those with chronotropic incompetence.[74] Exercise improves cardiac markers of autonomic function including heart rate recovery and heart rate variability among people with heart failure.[75, 76] Exercise has also been demonstrated to improve outcomes in POTS, which may also be related to autonomic responses to stress.[77, 78]

Limitations

The main limitations from this observational study arise from the convenience sampling, which may be prone to selection bias, and the cross-sectional nature of these advanced cardiovascular measures at a single time point. The first challenge is the classification of PASC—the statistical

significance and magnitude of the difference in peak VO_2 was sensitive to how we defined cardiopulmonary PASC. We do not have pre-COVID exercise tests and pre-COVID fitness is likely associated with post-COVID peak VO_2; if fitness is associated with risk of PASC, it would be an unmeasured confounder. Including individuals with a wide range of self-reported baseline-fitness widened our confidence intervals and reduced the precision of our estimates. Although we have adjusted for important measured confounders (ie age, sex, BMI) and conducted sensitivity analyses adjusting for other potential confounders (ie hypertension, asthma/COPD), there are likely residual confounders (including unmeasured ones, like pre-COVID fitness) that may bias our results. Although participants were not selected based on symptoms, volunteer bias may overestimate the prevalence of reduced exercise capacity and possibly the magnitude of the difference. We would not expect selection bias to affect the classification of those with limitations or the association with chronotropic incompetence among those with reduced peak VO_2. We did not include an uninfected comparator group, which could have strengthened our ability to make inferences about regardless of symptom status and definition. As others using cardiopulmonary exercise testing have previously noted, selecting an appropriate control group can be challenging. In terms of measurement, we did not perform invasive CPET, which would have allowed for assessment of peripheral oxygen extraction and preload response to exercise, nor did we perform stress echocardiography, stress CMR, or stress ventriculography; to do so would have required altering our exercise protocol which may have reduced our ability to detect chronotropic incompetence.

Conclusions

In conclusion, we found that reduced exercise capacity is common among individuals with prior SARS-CoV-2 infection and persistent cardiopulmonary symptoms at 18 months following

infection. Reduced exercise capacity in PASC is associated with chronotropic incompetence, ambulatory rhythm monitoring findings suggestive of autonomic dysfunction, and higher levels of hsCRP. While a significant proportion had trace or small pericardial effusions (also associated with hsCRP), we did not find evidence of prior or ongoing myocarditis. Further investigation into mechanisms of cardiopulmonary PASC should include study of the autonomic nervous system to identify potential therapeutic targets.

Acknowledgements: We would like to thank the research participants and the members of the LIINC team. We acknowledge the contributions of the UCSF Clinical and Translational Science Unit.

Funding: This study was funded by philanthropic gifts from Charles W. Swanson and the Ed and Pearl Fein Foundation, research grants from the NIH/NLBI including L30 HL159695 and K12 HL143961, and internal funds from the Division of Cardiology at Zuckerberg San Francisco General. Dr. Durstenfeld is funded by K12 HL143961. This work was assisted in part by a CFAR-ARI Boost Award from the UCSF AIDS Research Institute. JDK is supported by NIH/NIAID K23 AI135037. TJH is supported by NIH/NIAID 3R01A1141003-03S1. PYH is supported by NIH/NAID 2K24AI112393-06. This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1TR001872. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Disclosures: PYH has received modest honoraria from Gilead and Merck and research grant from Novartis unrelated to the submitted work. All other authors report no disclosures or conflicts.

References

1. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, Lekoubou A, Oh JS, Ericson JE, Ssentongo P and Chinchilli VM. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. *JAMA Netw Open*. 2021;4:e2128568.
2. Hirschtick JL, Titus AR, Slocum E, Power LE, Hirschtick RE, Elliott MR, McKane P and Fleischer NL. Population-Based Estimates of Post-acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (PASC) Prevalence and Characteristics. *Clin Infect Dis*. 2021;73:2055-2064.
3. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M and Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. *PLoS Med*. 2021;18:e1003773.
4. Piotr DA and Gaughan PC. Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. 2021.
5. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, Gundlapalli AV, Hall AJ and MacNeil A. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71:606-608.
6. Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL and Kulkarni PA. Postacute COVID-19: An Overview and Approach to Classification. *Open Forum Infect Dis*. 2020;7:ofaa509.
7. Durstenfeld MS, Peluso MJ, Kelly JD, Win S, Swaminathan S, Li D, Arechiga VM, Zepeda VA, Sun K, Shao SJ, Hill C, Arreguin MI, Lu S, Hoh R, Tai VW, Chenna A, Yee BC, Winslow JW, Petropoulos CJ, Kornak J, Henrich TJ, Martin JN, Deeks SG and Hsue PY. Role of antibodies, inflammatory markers, and echocardiographic findings in post-acute cardiopulmonary symptoms after SARS-CoV-2 infection. *JCI Insight*. 2022.
8. Fayol A, Livrozet M, Boutouyrie P, Khettab H, Betton M, Tea V, Blanchard A, Bruno RM, Hulot JS and French Ccsg. Cardiac performance in patients hospitalized with COVID-19: a 6 month follow-up study. *ESC Heart Fail*. 2021;8:2232-2239.
9. Tangen J, Aukrust P, Barratt-Due A, Skulstad H and Edvardsen T. Reduced Cardiac Function by Echocardiography in a Minority of COVID-19 Patients 3 Months after Hospitalization. *Journal of the American Society of Echocardiography*. 2022;35:243-244.
10. Catena C, Colussi G, Bulfone L, Da Porto A, Tascini C and Sechi LA. Echocardiographic Comparison of COVID-19 Patients with or without Prior Biochemical Evidence of Cardiac Injury after Recovery. *J Am Soc Echocardiogr*. 2021;34:193-195.
11. Wu X, Deng KQ, Li C, Yang Z, Hu H, Cai H, Zhang C, He T, Zheng F, Wang H, Zhang XA, Caillon A, Yuan Y, Wang X, Xu H and Lu Z. Cardiac Involvement in Recovered Patients From COVID-19: A Preliminary 6-Month Follow-Up Study. *Front Cardiovasc Med*. 2021;8:654405.
12. Sechi LA, Colussi G, Bulfone L, Brosolo G, Da Porto A, Peghin M, Patruno V, Tascini C and Catena C. Short-term cardiac outcome in survivors of COVID-19: a systematic study after hospital discharge. *Clin Res Cardiol*. 2021;110:1063-1072.
13. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina A, Escher F, Vasa-Nicotera M, Zeiher AM, Vehreschild M and Nagel E. Outcomes of

Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology*. 2020.
14. Joy G, Artico J, Kurdi H, Seraphim A, Lau C, Thornton GD, Oliveira MF, Adam RD, Aziminia N, Menacho K, Chacko L, Brown JT, Patel RK, Shiwani H, Bhuva A, Augusto JB, Andiapen M, McKnight A, Noursadeghi M, Pierce I, Evain T, Captur G, Davies RH, Greenwood JP, Fontana M, Kellman P, Schelbert EB, Treibel TA, Manisty C and Moon JC. Prospective Case-Control Study of Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers. *JACC: Cardiovascular Imaging*. 2021;14:2155-2166.
15. Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, Patel R, Chacko L, Brown JT, Coyle C, Leith D, Shetye A, Ariff B, Bell R, Captur G, Coleman M, Goldring J, Gopalan D, Heightman M, Hillman T, Howard L, Jacobs M, Jeetley PS, Kanagaratnam P, Kon OM, Lamb LE, Manisty CH, Mathurdas P, Mayet J, Negus R, Patel N, Pierce I, Russell G, Wolff A, Xue H, Kellman P, Moon JC, Treibel TA, Cole GD and Fontana M. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. *Eur Heart J*. 2021.
16. Roca-Fernandez A, Wamil M, Telford A, Carapella V, Borlotti A, Monteiro D, Thomaides-Brears H, Kelly MD, Dennis A, Banerjee R, Robson M, Brady M, Lip G, Bull S, Heightman MJ, Ntusi N and Banerjee A. Cardiac impairment in Long Covid 1-year post-SARS-CoV-2

infection. *Preprint medRxiv 2022*. 2022.
17. Cassar MP, Tunnicliffe EM, Petousi N, Lewandowski AJ, Xie C, Mahmod M, Samat AHA, Evans RA, Brightling CE, Ho LP, Piechnik SK, Talbot NP, Holdsworth D, Ferreira VM, Neubauer S and Raman B. Symptom Persistence Despite Improvement in Cardiopulmonary Health - Insights from longitudinal CMR, CPET and lung function testing post-COVID-19. *EClinicalMedicine*. 2021;41:101159.
18. Aparisi A, Ybarra-Falcon C, Garcia-Gomez M, Tobar J, Iglesias-Echeverria C, Jaurrieta-Largo S, Ladron R, Uribarri A, Catala P, Hinojosa W, Marcos-Mangas M, Fernandez-Prieto L, Sedano-Gutierrez R, Cusacovich I, Andaluz-Ojeda D, de Vega-Sanchez B, Recio-Platero A, Sanz-Patino E, Calvo D, Baladron C, Carrasco-Moraleja M, Disdier-Vicente C, Amat-Santos IJ and San Roman JA. Exercise Ventilatory Inefficiency in Post-COVID-19 Syndrome: Insights from a Prospective Evaluation. *J Clin Med*. 2021;10.
19. Barbagelata L, Masson W, Iglesias D, Lillo E, Migone JF, Orazi ML and Maritano Furcada J. Cardiopulmonary Exercise Testing in Patients with Post-COVID-19 Syndrome. *Med Clin (Barc)*. 2021.
20. Skjorten I, Ankerstjerne OAW, Trebinjac D, Bronstad E, Rasch-Halvorsen O, Einvik G, Lerum TV, Stavem K, Edvardsen A and Ingul CB. Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation. *Eur Respir J*. 2021;58.
21. Szekely Y, Lichter Y, Sadon S, Lupu L, Taieb P, Banai A, Sapir O, Granot Y, Hochstadt A, Friedman S, Laufer-Perl M, Banai S and Topilsky Y. Cardiorespiratory Abnormalities in Patients Recovering from Coronavirus Disease 2019. *J Am Soc Echocardiogr*. 2021;34:1273-1284.e9.
22. Ingul CB, Grimsmo J, Mecinaj A, Trebinjac D, Berger Nossen M, Andrup S, Grenne B, Dalen H, Einvik G, Stavem K, Follestad T, Josefsen T, Omland T and Jensen T. Cardiac Dysfunction and Arrhythmias 3 Months After Hospitalization for COVID-19. *J Am Heart Assoc*. 2022;11:e023473.

23. Dewland TA, Whitman IR, Win S, Sanchez JM, Olgin JE, Pletcher MJ, Santhosh L, Kumar U, Joyce S, Yang V, Hwang J, Ogomori K, Peyser N, Horner C, Wen D, Butcher X and Marcus GM. Prospective arrhythmia surveillance after a COVID-19 diagnosis. *Open Heart*. 2022;9.
24. Peluso MJ, Kelly JD, Lu S, Goldberg SA, Davidson MC, Mathur S, Durstenfeld MS, Spinelli MA, Hoh R, Tai V, Fehrman EA, Torres L, Hernandez Y, Williams MC, Arreguin MI, Ngo LH, Deswal M, Munter SE, Martinez EO, Anglin KA, Romero MD, Tavs J, Rugart PR, Chen JY, Sans HM, Murray VW, Ellis PK, Donohue KC, Massachi JA, Weiss JO, Mehdi I, Pineda-Ramirez J, Tang AF, Wenger MA, Assenzio MT, Yuan Y, Krone MR, Rutishauser RL, Rodriguez-Barraquer I, Greenhouse B, Sauceda JA, Gandhi M, Scheffler AW, Hsue PY, Henrich TJ, Deeks SG and Martin JN. Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. *Open Forum Infectious Diseases*. 2021;9.
25. Hansen JE, Sue DY and Wasserman K. Predicted values for clinical exercise testing. *Am Rev Respir Dis*. 1984;129:S49-55.
26. Wasserman K HJ, Sue DY, Stringer W, Whipp BJ. *Principles of Exercise Testing and Interpretation.* 4th ed. Philadelpha: Lippincott Williams and Wilkins; 2005.
27. Arena R, Myers J, Abella J, Pinkstaff S, Brubaker P, Moore B, Kitzman D, Peberdy MA, Bensimhon D, Chase P, Forman D, West E and Guazzi M. Determining the preferred percent-predicted equation for peak oxygen consumption in patients with heart failure. *Circ Heart Fail*. 2009;2:113-20.
28. Brubaker PH and Kitzman DW. Chronotropic Incompetence. *Circulation*. 2011;123:1010-1020.
29. Schaeffer MR, Cowan J, Milne KM, Puyat JH, Voduc N, Corrales-Medina V, Lavoie KL, Mulloy A, Chirinos JA, Abdallah SJ and Guenette JA. Cardiorespiratory physiology, exertional symptoms, and psychological burden in post-COVID-19 fatigue. *Respir Physiol Neurobiol*. 2022;302:103898.
30. Brown JT, Saigal A, Karia N, Patel RK, Razvi Y, Constantinou N, Steeden JA, Mandal S, Kotecha T, Fontana M, Goldring J, Muthurangu V and Knight DS. Ongoing Exercise Intolerance Following COVID-19: A Magnetic Resonance-Augmented Cardiopulmonary Exercise Test Study. *J Am Heart Assoc*. 2022;11:e024207.
31. Singh I, Joseph P, Heerdt PM, Cullinan M, Lutchmansingh DD, Gulati M, Possick JD, Systrom DM and Waxman AB. Persistent Exertional Intolerance After COVID-19: Insights From Invasive Cardiopulmonary Exercise Testing. *Chest*. 2022;161:54-63.
32. Joseph P, Arevalo C, Oliveira RKF, Faria-Urbina M, Felsenstein D, Oaklander AL and Systrom DM. Insights From Invasive Cardiopulmonary Exercise Testing of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Chest*. 2021;160:642-651.
33. Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, Forman CA, Munter SE, Hoh R, Tai V, Chenna A, Yee BC, Winslow JW, Petropoulos CJ, Greenhouse B, Hunt PW, Hsue PY, Martin JN, Daniel Kelly J, Glidden DV, Deeks SG and Henrich TJ. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J Infect Dis*. 2021.
34. Kistner TM, Pedersen BK and Lieberman DE. Interleukin 6 as an energy allocator in muscle tissue. *Nat Metab*. 2022;4:170-179.

35. Mancini DM, Brunjes DL, Lala A, Trivieri MG, Contreras JP and Natelson BH. Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post-Coronavirus Disease. *JACC Heart Fail*. 2021;9:927-937.
36. Fresard I, Genecand L, Altarelli M, Gex G, Vremaroiu P, Vremaroiu-Coman A, Lawi D and Bridevaux PO. Dysfunctional breathing diagnosed by cardiopulmonary exercise testing in 'long COVID' patients with persistent dyspnoea. *BMJ Open Respir Res*. 2022;9:e001126.
37. Motiejunaite J, Balagny P, Arnoult F, Mangin L, Bancal C, Vidal-Petiot E, Flamant M, Jondeau G, Cohen-Solal A, d'Ortho MP and Frija-Masson J. Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors. *Eur Respir J*. 2021;58:2101578.
38. Abdallah SJ, Voduc N, Corrales-Medina VF, McGuinty M, Pratt A, Chopra A, Law A, Garuba HA, Thavorn K, Reid RER, Lavoie KL, Crawley A, Chirinos JA and Cowan J. Symptoms, Pulmonary Function, and Functional Capacity Four Months after COVID-19. *Ann Am Thorac Soc*. 2021;18:1912-1917.
39. Jimeno-Almazán A, Pallarés JG, Buendía-Romero Á, Martínez-Cava A and Courel-Ibáñez J. Chronotropic Incompetence in Non-Hospitalized Patients with Post-COVID-19 Syndrome. *Journal of Clinical Medicine*. 2021;10:5434.
40. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D and Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. *N Engl J Med*. 2005;352:1951-8.
41. Ladlow P, O'Sullivan O, Houston A, Barker-Davies R, May S, Mills D, Dewson D, Chamley R, Naylor J, Mulae J, Bennett AN, Nicol ED and Holdsworth DA. Dysautonomia following COVID-19 is not associated with subjective limitations or symptoms but is associated with objective functional limitations. *Heart Rhythm*. 2022;19:613-620.
42. Savonen KP, Lakka TA, Laukkanen JA, Halonen PM, Rauramaa TH, Salonen JT and Rauramaa R. Heart rate response during exercise test and cardiovascular mortality in middle-aged men. *European Heart Journal*. 2006;27:582-588.
43. Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE and Marwick TH. Impaired Chronotropic Response to Exercise Stress Testing as a Predictor of Mortality. *JAMA*. 1999;281:524-529.
44. Huang PH, Leu HB, Chen JW, Wu TC, Lu TM, Ding YA and Lin SJ. Comparison of endothelial vasodilator function, inflammatory markers, and N-terminal pro-brain natriuretic peptide in patients with or without chronotropic incompetence to exercise test. *Heart*. 2006;92:609-14.
45. Paneroni M, Pasini E, Vitacca M, Scalvini S, Comini L, Pedrinolla A and Venturelli M. Altered Vascular Endothelium-Dependent Responsiveness in Frail Elderly Patients Recovering from COVID-19 Pneumonia: Preliminary Evidence. *J Clin Med*. 2021;10.
46. Mejia-Renteria H, Travieso A, Sagir A, Martínez-Gómez E, Carrascosa-Granada A, Toya T, Núñez-Gil IJ, Estrada V, Lerman A and Escaned J. In-vivo evidence of systemic endothelial vascular dysfunction in COVID-19. *International Journal of Cardiology*. 2021;345:153-155.
47. Ambrosino P, Parrella P, Formisano R, Perrotta G, D'Anna SE, Mosella M, Papa A and Maniscalco M. Cardiopulmonary Exercise Performance and Endothelial Function in Convalescent COVID-19 Patients. *J Clin Med*. 2022;11.
48. Drakos S, Chatzantonis G, Bietenbeck M, Evers G, Schulze AB, Mohr M, Fonfara H, Meier C and Yilmaz A. A cardiovascular magnetic resonance imaging-based pilot study to assess coronary microvascular disease in COVID-19 patients. *Sci Rep*. 2021;11:15667.

49. Bechsgaard DF, Hove JD, Suhrs HE, Bové KB, Shahriari P, Gustafsson I and Prescott E. Women with coronary microvascular dysfunction and no obstructive coronary artery disease have reduced exercise capacity. *International Journal of Cardiology*. 2019;293:1-9.
50. Kim B-J, Jo E-A, Im S-I, Kim H-S, Heo JH and Cho K-I. Heart rate recovery and blood pressure response during exercise testing in patients with microvascular angina. *Clinical Hypertension*. 2019;25:4.
51. Novak P, Mukerji SS, Alabsi HS, Systrom D, Marciano SP, Felsenstein D, Mullally WJ and Pilgrim DM. Multisystem Involvement in Post-Acute Sequelae of Coronavirus Disease 19. *Ann Neurol*. 2022;91:367-379.
52. Oaklander AL, Mills AJ, Kelley M, Toran LS, Smith B, Dalakas MC and Nath A. Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID. *Neurol Neuroimmunol Neuroinflamm*. 2022;9.
53. Li Y-C, Zhang Y and Tan B-H. What can cerebrospinal fluid testing and brain autopsies tell us about viral neuroinvasion of SARS-CoV-2. *Journal of Medical Virology*. 2021;93:4247-4257.
54. Peluso MJ, Sans HM, Forman CA, Nylander AN, Ho H-e, Lu S, Goldberg SA, Hoh R, Tai V, Munter SE, Chenna A, Yee BC, Winslow JW, Petropoulos CJ, Martin JN, Kelly JD, Durstenfeld MS, Hsue PY, Hunt PW, Greene M, Chow FC, Hellmuth J, Henrich TJ, Glidden DV and Deeks SG. Plasma markers of neurologic injury and systemic inflammation in individuals with self-reported neurologic post-acute sequelae of SARS-CoV-2 infection (PASC). *medRxiv*. 2021:2021.11.02.21265778.
55. Apple AC, Oddi A, Peluso MJ, Asken BM, Henrich TJ, Kelly JD, Pleasure SJ, Deeks SG, Allen IE, Martin JN, Ndhlovu LC, Miller BL, Stephens ML and Hellmuth J. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. *Ann Clin Transl Neurol*. 2022;9:221-226.
56. Halaris A. Inflammation-Associated Co-morbidity Between Depression and Cardiovascular Disease. *Curr Top Behav Neurosci*. 2017;31:45-70.
57. Williams DP, Koenig J, Carnevali L, Sgoifo A, Jarczok MN, Sternberg EM and Thayer JF. Heart rate variability and inflammation: A meta-analysis of human studies. *Brain Behav Immun*. 2019;80:219-226.
58. Stute NL, Stickford JL, Province VM, Augenreich MA, Ratchford SM and Stickford ASL. COVID-19 is getting on our nerves: sympathetic neural activity and haemodynamics in young adults recovering from SARS-CoV-2. *J Physiol*. 2021;599:4269-4285.
59. Ribeiro Baptista B, d'Humieres T, Schlemmer F, Bendib I, Justeau G, Al-Assaad L, Hachem M, Codiat R, Bardel B, Abou Chakra L, Belmondo T, Audureau E, Hue S, Mekontso-Dessap A, Derumeaux G and Boyer L. Identification of factors impairing exercise capacity after severe COVID-19 pulmonary infection: a 3-month follow-up of prospective COVulnerability cohort. *Respir Res*. 2022;23:68.
60. Franssen WMA, Keytsman C, Marinus N, Verboven K, Eijnde BO, van Ryckeghem L, Dendale P, Zeevaert R, Massa G and Hansen D. Chronotropic incompetence is more frequent in obese adolescents and relates to systemic inflammation and exercise intolerance. *J Sport Health Sci*. 2021.
61. Benes J, Kotrc M, Borlaug BA, Lefflerova K, Jarolim P, Bendlova B, Jabor A, Kautzner J and Melenovsky V. Resting heart rate and heart rate reserve in advanced heart failure have distinct pathophysiologic correlates and prognostic impact: a prospective pilot study. *JACC Heart Fail*. 2013;1:259-66.

62. Tawakol A, Ishai A, Takx RA, Figueroa AL, Ali A, Kaiser Y, Truong QA, Solomon CJ, Calcagno C, Mani V, Tang CY, Mulder WJ, Murrough JW, Hoffmann U, Nahrendorf M, Shin LM, Fayad ZA and Pitman RK. Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. *Lancet*. 2017;389:834-845.
63. Tawakol A, Osborne MT, Wang Y, Hammed B, Tung B, Patrich T, Oberfeld B, Ishai A, Shin LM, Nahrendorf M, Warner ET, Wasfy J, Fayad ZA, Koenen K, Ridker PM, Pitman RK and Armstrong KA. Stress-Associated Neurobiological Pathway Linking Socioeconomic Disparities to Cardiovascular Disease. *J Am Coll Cardiol*. 2019;73:3243-3255.
64. Tell D, Burr RL, Mathews HL and Janusek LW. Heart Rate Variability and Inflammatory Stress Response in Young African American Men: Implications for Cardiovascular Risk. *Front Cardiovasc Med*. 2021;8:745864.
65. Fonkoue IT, Marvar PJ, Norrholm S, Li Y, Kankam ML, Jones TN, Vemulapalli M, Rothbaum B, Bremner JD, Le NA and Park J. Symptom severity impacts sympathetic dysregulation and inflammation in post-traumatic stress disorder (PTSD). *Brain Behav Immun*. 2020;83:260-269.
66. Sollini M, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, Gelardi F and Chiti A. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/CT study. *European Journal of Nuclear Medicine and Molecular Imaging*. 2021;48:1460-1466.
67. Sanders P, Kistler PM, Morton JB, Spence SJ and Kalman JM. Remodeling of sinus node function in patients with congestive heart failure: reduction in sinus node reserve. *Circulation*. 2004;110:897-903.
68. Han Y, Zhu J, Yang L, Nilsson-Payant BE, Hurtado R, Lacko LA, Sun X, Gade AR, Higgins CA, Sisso WJ, Dong X, Wang M, Chen Z, Ho DD, Pitt GS, Schwartz RE, tenOever BR, Evans T and Chen S. SARS-CoV-2 Infection Induces Ferroptosis of Sinoatrial Node Pacemaker Cells. *Circ Res*. 2022;130:963-977.
69. Clavario P, De Marzo V, Lotti R, Barbara C, Porcile A, Russo C, Beccaria F, Bonavia M, Bottaro LC, Caltabellotta M, Chioni F, Santangelo M, Hautala AJ, Griffo R, Parati G, Corrà U and Porto I. Cardiopulmonary exercise testing in COVID-19 patients at 3 months follow-up. *Int J Cardiol*. 2021;340:113-118.
70. Rinaldo RF, Mondoni M, Parazzini EM, Pitari F, Brambilla E, Luraschi S, Balbi M, Sferrazza Papa GF, Sotgiu G, Guazzi M, Di Marco F and Centanni S. Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors. *Eur Respir J*. 2021;58:2100870.
71. Borrego Rodriguez J, Berenguel Senen A, De Cabo Porras C, Gallango Brejano M, Gigante Miravalles E, Morante Perea C, Serrano Blanco A, Gadella Fernandez A, Martinez Camara A, Sanchez-Aguilera Sanchez-Paulete P, Lazaro Salvador M, Flores Hernan M, Lozano Lazaro MG, Arias Palomares MA and Rodriguez Padial L. Cardiopulmonary exercise test in patients with persistent dyspnea after COVID-19 disease. *European Heart Journal*. 2021;42.
72. Jahn K, Sava M, Sommer G, Schumann DM, Bassetti S, Siegemund M, Battegay M, Stolz D, Tamm M, Khanna N and Hostettler KE. Exercise capacity impairment after COVID-19 pneumonia is mainly caused by deconditioning. *The European respiratory journal*. 2021;59:2101136.
73. Aranyó J, Bazan V, Lladós G, Dominguez MJ, Bisbal F, Massanella M, Sarrias A, Adeliño R, Riverola A, Paredes R, Clotet B, Bayés-Genís A, Mateu L and Villuendas R. Inappropriate sinus tachycardia in post-COVID-19 syndrome. *Scientific Reports*. 2022;12:298.

74. Keteyian SJ, Brawner CA, Schairer JR, Levine TB, Levine AB, Rogers FJ and Goldstein S. Effects of exercise training on chronotropic incompetence in patients with heart failure. *Am Heart J*. 1999;138:233-40.
75. Kiilavuori K, Toivonen L, Näveri H and Leinonen H. Reversal of autonomic derangements by physical training in chronic heart failure assessed by heart rate variability. *Eur Heart J*. 1995;16:490-5.
76. Myers J, Hadley D, Oswald U, Bruner K, Kottman W, Hsu L and Dubach P. Effects of exercise training on heart rate recovery in patients with chronic heart failure. *Am Heart J*. 2007;153:1056-63.
77. Fu Q and Levine BD. Exercise and non-pharmacological treatment of POTS. *Auton Neurosci*. 2018;215:20-27.
78. George SA, Bivens TB, Howden EJ, Saleem Y, Galbreath MM, Hendrickson D, Fu Q and Levine BD. The international POTS registry: Evaluating the efficacy of an exercise training intervention in a community setting. *Heart Rhythm*. 2016;13:943-50.

Figure 1. Exercise Capacity Among those with and without Cardiopulmonary Symptoms (n=39)



Figure 1 Legend: On the left are box and whisker plots of unadjusted peak oxygen consumption (VO_2 in ml/kg/min on the left and percent of predicted on the right) among those without (blue) and with chest pain, dyspnea, or palpitations (pink). Mean peak VO_2 was 22.1 ml/kg/min among those with cardiopulmonary symptoms compared to 26.0 ml/kg/min among those without symptoms, a non-statistically significant difference of -3.9 ml/kg/min (95%CI -1.7 to 9.6; p=0.17) or 92% vs 103% percent predicted (difference -10.5, 95%CI -5.0 to 26.1; p=0.18). After adjustment for age, sex, hospitalization for acute COVID, BMI category, and months since SARS-CoV-2 infection, peak VO_2 was 2.7 ml/kg/min lower among those reporting cardiopulmonary symptoms (95%CI -6.9 to 1.5; p=0.20) which is equivalent to 11% lower than predicted (95%CI -27 to 5, p=0.17), neither of which were statistically significant differences.

Figure 2. Percent Predicted Peak VO_2 by Chronotropic Response to Exercise



Figure 2 Legend: Boxplots of peak VO_2 (percent predicted since both are confounded by age) by reaching an AHRR >80% (normal chronotropic response to exercise) or <80% (blunted chronotropic response to exercise). P value is for unadjusted t-test. Not reaching adjusted heart rate reserve >80% during CPET was associated with 15.6x higher odds of having reduced exercise capacity <85% predicted (95%CI 1.30-187; p=0.03).

Figure 3. Heart Rate During Exercise by Chronotropic Response



Figure 3 Legend: These lines represent the average heart rate at a given percentage of exercise completed classified by normal exercise capacity and chronotropic response during exercise on the top in purple (peak $VO_2 \geq 85\%$ predicted and AHRR ≥80%; R^2 0.89), normal exercise capacity with reduced chronotropic response in teal (peak VO2≥85% predicted and AHRR <80%; R^2 0.90), and reduced exercise capacity with chronotropic incompetence in yellow (peak $VO_2 < 85\%$ predicted and AHRR <80%; R^2 0.75). Gray bars represent 95% confidence intervals for each fitted line. Results are similar when plotting %APMHR or AHRR instead of absolute heart rate (Supplemental figure 1).

Figure 4. Inflammation, Peak VO_2 and Heart Rate Response to Exercise



Figure 4 Legend. Boxplots of peak VO_2 and adjusted heart rate reserve (AHRR) by hsCRP less than or greater than median (1.2 mg/L). Peak VO_2 decreases by 1.8 ml/kg/min per doubling of hsCRP (95%CI 0.2 to 3.3; p=0.03) or 6.3% reduction per doubling (95%CI 0.6 to 12; p=0.03); when treated as a dichotomous variable, the odds of reduced peak VO_2 <85% predicted were 1.96 per doubling of hsCRP (0.84-4.56; p=0.12). Adjusted heart rate reserve is 2.5% lower per doubling of hsCRP (95%CI -9 to 4; p=0.44), which was not statistically significant.

Table 1: Baseline Characteristics for All Participants (n=120)

	Symptoms (N=56)	No Symptoms (N=64)	OR (95%CI; p)
Months since infection	6.8 (4.0, 8.5)	6.4 (3.6, 9.2)	1.01 (0.89-1.15; p=0.90)
Age, median [IQR]	51 [40, 58]	55 [47, 60]	0.80 (0.56- 1.14; p=0.21)
Female Sex	27 (48%)	18 (28%)	2.06 (0.90-4.73; p=0.09)
Hispanic/Latino/Latina/Latinx	17 (30%)	11 (17%)	Reference
Black/African American	1 (2%)	6 (9%)	0.12 (0.01-1.72; p=0.12)
Asian/Pacific Islander	5 (9%)	7 (11%)	0.34 (0.07-1.72; p=0.17
White	32 (57%)	40 (63%)	0.86 (0.29-2.51; p=0.78)
Hypertension	10 (21%)	18 (33%)	0.59 (0.19-1.81; p=0.35)
Diabetes	5 (11%)	4 (8%)	2.23 (0.32-15.4; p=0.42)
Asthma/COPD	12 (26%)	11 (20%)	1.40 (0.45-4.41; p=0.56)
HIV	13 (24%)	28 (44%)	0.48 (0.17-1.34; p=0.16)
Former or Current Smoker	16 (34%)	19 (35%)	1.44 (0.52-4.04; p=0.48)
BMI, kg/m^2	30.0+/-8.3	27.5+/-5.0	1.08 (0.99-1.19; p=0.10)
BMI Category			
24.9 or less	18 (33%)	19 (31%)	Reference
25 to 29.9	11 (20%)	27 (44%)	0.19 (0.04-0.97; p=0.046)
30 to 34.9	14 (25%)	11 (18%)	1.40 (0.31-6.29; p=0.66)
35 or greater	12 (22%)	5 (8%)	2.12 (0.23-19.2; p=0.50)
Hospitalized for Acute COVID	15 (28%)	8 (13%)	3.93 (1.47-10.5; p=0.006)
hsCRP	0.9 (0.4, 1.7)	1.8 (0.8, 4.9)	1.36 per doubling (1.00-1.87; p=0.05)
LVEF, %	63.5±5.6	63.9±2.9	0.98 (0.91-1.04;p=0.47)

Table 1 Legend: There were no significant differences between the entire cohort, shown here, and the subset who underwent advanced cardiopulmonary testing (Supplemental Table 1), with the exception of earlier date of infection. Hospitalization, elevated hsCRP, and possibly female sex were associated with symptoms. Abbreviations: BMI=body mass index hsCRP=high sensitivity c-reactive protein, LVEF=Left Ventricular Ejection Fraction, OR=odds ratio

Table 2: Cardiopulmonary Exercise Testing Parameters by Symptom Status (n=39)

	Measure	Symptoms (n=17)	No Symptoms (n=22)	Adjusted OR (95%CI; p value)	Adjusted Difference (95%CI; p value)
Exertion	Work (Watts)	144±60	167±71	1.24 per 10 watt decrease (0.98-1.56; p=0.07)	-15 (-57 to 26; p=0.46)
	Perceived Exertion, Borg Scale 6-20	15.9±1.7	15.1±2.1	1.58 (0.91-2.73; p=0.10)	1.0 (-0.3 to 2.4; p=0.14)
	Respiratory Exchange Ratio (VCO_2/VO_2)	1.2 (1.1, 1.3)	1.2 (1.1, 1.3)	0.78 per 0.1 decrease (0.34-1.78; p=0.56)	0.02 (-0.06 to 0.09; p=0.62)
Exercise Capacity	Peak VO_2, ml/kg/min	22.1±9.3	26.0±8.2	0.89 (0.76-1.05; p=0.17)	-2.7 (-6.8 to 1.5; p=0.20)
	Peak VO_2, % predicted	11.2±3.3	12.4±4.2	0.97 (0.93-1.01; p=0.14)	-10.9 (-26.7 to 4.9; p=0.17
	Peak VO_2 <85% predicted	9 (53%)	7 (32%)	6.36 (0.86-41.1; p=0.07)	21 (-10 to 52; p=0.18)
	VO_2AT (ml/kg/min)	10.8 (8.9, 12.6)	11.8 (10.2, 15.2)	0.85 (0.65-1.10; p=0.21)	-1.3 (-3.6 to 1.1; p=0.29)
	VO_2AT % Pred. Peak	47.8±8.2	53.0±12.8	2.13 (1.08-4.20; p=0.03)	-7.7 (-14.8 to -0.6; p=0.04)
	Weber Class A (pVO_2>20) B (pVO_2 16-20) C (pVO_2 10-16)	 9 (53%) 3 (18%) 5 (29%)	 15 (71%) 4 (19%) 2 (10%)	p=0.24 Ref 1.23 (0.07-21.5) 14.9 (0.4-566)	--
Ventila-tory	Rest Respiratory Rate	16.5±5.2	16.2±5.4	1.04 (0.90-1.21; p =0.58)	0.9 (-3 to 5; p=0.65)
	Peak Respiratory Rate	37±8	39±9	0.95 (0.85-1.05; p=0.32)	-2.7 (-9 to 4; p=0.41)
	Tidal Volume (%FVC)	52±8	56±12	0.88 per 10% increase (0.40-1.94; p=0.75)	1.1 (-9.3 to 7.0; p=0.78)
	VD/VT	0.17±0.04	0.18±0.03	1.01 per 10% increase (0.76-1.37; p=0.90)	0.002 (-0.02 to 0.02; p=0.87)
	Breathing Reserve	43 [38,51]	40 [27, 53]	1.03 (0.97-1.08; p=0.31)	5.3 (-7.6 to 18; p=0.41)
	Ventilatory Efficiency (VE/VCO2 slope)	27.3±3.8	26.8±4.1	1.10 (0.89-1.35; p=0.38)	1.2 (-1.8 to 4.2; p=0.43)
	Ventilatory Class I (VE/VCO_2 slope <30) II (VE/VCO_2 slope 30-36)	 13 (76%) 4 (24%)	 13 (65%) 7 (35%)	p=0.71 ref 0.69 (0.10-4.93)	--
Peripheral	VO_2 to Work slope	10.1±8.8	10.3±8.2	1.08 (0.86 to 1.35; p=0.51)	0.70 (-2.1 to 3.4; p=0.61)

Cardiac	VO_2 pulse, ml/beat	12.7±2.6	14.4±4.4	0.89 (0.68-1.16; p=0.38)	-1.1 (-3.7 to 1.4; p=0.37)
	SBP peak, mm Hg	169±38	182±25	1.00 (0.97-1.03; p=0.91)	0.5 (-22 to 23; p=0.96)
	DBP peak, mm Hg	88±13	83±11	1.04 (0.97-1.12; p=0.24)	5.3 (-4 to 14; p=0.24)
	Ischemic ECG Changes	1	0	---	---
Heart Rate	Rest, bpm	79±16	77±13	0.99 (0.93-1.06; p=0.78)	-1.4 (-11 to 8; p=0.77)
	Peak, bpm	150±26	148±23	0.99 (0.95-1.04; p = 0.78)	-1.1 (-15 to 13; p=0.87)
	Peak, % Age Predicted	88±12%	89±13%	0.98 (0.91-1.06; p=0.65)	-1.3 (-10 to 7; p=0.77)
	Adj. HR Reserve Achieved, %	76±23%	79±24%	0.99 (0.95-1.03; p=0.64)	-2.3 (-18 to 14; p=0.77)
	Recovery 1 min, bpm	15±8	13±8	1.10 (0.97-1.25; p=0.12)	4.1 (-1.5 to 9.8; p=0.15)

Table 2 Legend: We present both the odds ratios for the association between CPET parameters and cardiopulmonary symptoms estimated using logistic regression with adjustment for age, sex, time since COVID, hospitalization for acute COVID, BMI category; we also estimated mean differences between those with and without symptoms using linear regression and adjusting for the same covariates. Sensitivity analysis incorporating history of hypertension, diabetes, and lung disease had no substantive changes in effect sizes or confidence intervals.

Table 3. Cardiac MRI Parameters (n=39) by Symptom Status

Meaning	Parameter	Symptoms (n=15)	No Symptoms (n=24)	Adjusted OR (95%CI; p value)	Adjusted Difference (95%CI; p value)
Months since SARS-CoV-2 Infection		14.9±3.3	16.0±3.7	0.92 (0.72 to 1.18; p=0.51)	-0.8 (-3.8 to 2.2; p=0.58)
Left Ventricular Size and Function	LVEDi, ml/m^2 LVESi, ml/m^2	67 [45, 77] 25 [17, 32]	70 [58, 77] 25 [21, 31]	1.39 per 5ml decrease (0.93-2.06; p=0.11) 1.18 per 5ml decrease (0.62-2.24; p=0.62)	-7.4 (-17 to 2.5; p=0.14) -1.2 (-6 to 4; p=0.63)
	LVEF, % LVEF <50%	59.5 [57.0, 62.0] 0	63.0 [58.0, 68.0] 0	1.52 per 5% decrease (0.73-3.19; p=0.27)	-2.1 (-6.7 to 2.6; p=0.37)
	LV Mass Index, gm/m^2	46.5±7.9	49.25±7.4	1.26 per 5gm/m^2 decrease (0.67 to 2.39; p=0.47)	-1.8 (-7.0 to 3.4; p=0.49)
	Stroke Volume, ml*	73.0±18.4	82.3±18.8	1.45 per 5 ml decrease (1.02-2.05; p=0.04)	-16 (-29 to -3; p=0.02)
Right Ventricular Size and Function	RVEDi, ml/m^2 RVESi, ml/m^2	64 [48, 79] 27 [22, 33]	72 [64, 81] 30 [24, 35]	1.69 per 5ml decrease (1.08 to 2.68; p=0.02) 3.57 per 5ml decrease (1.09 to 11.8; p=0.04)	-10.8 (-19.7 to -2.0; p=0.02) -4.4 (-8.2 to -0.6; p=0.03)
	RVEF, % RVEF<50%	58±4% 0	60±5% 0	1.50 per 5% decrease (0.53-4.24; p=0.44)	-1.1 (-4.5 to 2.3; p=0.52)
Markers of Cardiac Inflammation	T1 Native Mapping, ms	1201 [1163, 1253]	1216 [1155, 1258]	1.00 (0.99-1.01; p=0.40)	0.98x (0.92 to 1.05; p=0.51)
	T2 Native Mapping, ms	47.1±5.6	47.8±4	0.99 (0.83-1.19; p=0.95)	-0.2 (-4.4 to 4.0; p=0.93)
	Extracellular Volume, %	28.4±6.6	24.1±4.1	1.49 (0.97-2.29; p=0.07)	4.4 (0.51 to 8.30; p=0.03)
Cardiac Fibrosis	Late Gadolinium Enhancement	0	0	--	--
Possible Pericardial Inflammation	Pericardial Effusion	5 (25%)	6 (33%)	1.26 (0.16-10.0; p=0.83)	--

Table 3 Legend: CMR parameters by cardiopulmonary symptoms given as mean±SD or median [intraquartile range] for non-normally distributed variables. Logistic regression was used to estimated odds of having symptoms for a given change in each parameter adjusted for age, sex, BMI category, hospitalization, and time since infection and linear regression was used to estimate mean differences between those with and without symptoms adjusted for the same likely confounders. Abbreviations: LVEDi=Left ventricular end diastolic volume indexed to body surface area. LVESi=Left ventricular end diastolic volume indexed to body surface area. RVEDi=Right ventricular end diastolic volume indexed to body surface area. RVESi=Right ventricular end diastolic volume indexed to body surface area. LVEF=Left ventricular ejection fraction. RVEF=Right ventricular Ejection Fraction. *LV stroke volumes are reported but there is a high correlation between LV and RV stroke volumes (Pearson's r=0.96).

Table 4. Ambulatory Rhythm Monitoring Findings by Symptoms (n=38)

Parameter	Symptoms (n=14)	No Symptoms (n=24)	Adjusted OR (95%CI; p value)	Adjusted difference (95%CI CI; p value)
Monitoring Time, days	4 (3, 14)	5 (3, 11)	0.97 (0.77 to 1.24; p=0.83)	-0.3 (-3 to 3; p=0.82)
Average Heart Rate, bpm	78±12	76±8	1.01 (0.92 to 1.10; p=0.90)	0.3 (-7 to 8; p=0.94)
Minimum HR, bpm	52±16	46±5	1.09 (0.96-1.24; p=0.18)	5.0 (-2.8 to 12.7; p=0.20)
Maximum HR, bpm	142±19	153±21	2.85 per 10 decrease (0.83-9.77; p=0.10)	-8 (-18 to 2; p=0.12)
Maximum HR, % predicted	84±9	92±11	1.75 per 10 decrease (0.92-3.32; p=0.09)	-8 (-15 to -0.8; p=0.03)
Adjusted HRR achieved, %	69±20	86±21	1.77 per 10 decrease (0.89-3.51; p=0.10)	-9.9 (-23 to 3; p=0.12)
Heart Rate Variability, SDNN	147±77	158±29	1.10 per 10 decrease (0.92 to 1.31; p=0.29)	-18 (-60 to 25; p=0.40)
PAC, % burden	0.015 (0.01, 0.09)	0.01 (0.01, 0.04)	3.38 per 10-fold increase (0.36 to 31.6; p=0.29)	1.5x (0.56 to 4.5; p=0.36)
PVC, % burden	0.01 (0.01, 0.1)	0.01 (0, 0.01)	1.78 per 10-fold increase (0.86 to 3.66; p=0.12)	6.0x (0.51 to 72; p=0.15)
Sinus tachycardia, % burden	4 (2, 7)	4.5 (3, 12)	1.02 (0.95 to 1.10; p=0.61)	2.1 (-7.8 to 12.1; p=0.66)
Episodes of SVT* per week	0 (0, 4)	1 (0, 3)	1.00 (0.88 to 1.14; p =0.97)	0.2 (-4.6 to 5.0; p=0.93)
Episodes of Nonsustained VT	0	1	--	--
Button Pushes	2.5 (1,6)	1 (0, 3)	2.0 if 2 or more times (0.49 to 8.4; p=0.33)	2.2x (1.6-3.1; p<0.001)

Table 4 Legend. Values are reported as mean±SD or median (interquartile range) for non-normally distributed variables assessed by histogram. The only statistically significant difference between those with and without symptoms was the number of button pushes, which was 2.4 time more among those with symptoms (95CI% 1.7-3.4; p<0.001), and lower maximum sinus heart rate consistent with chronotropic incompetence among those with symptoms. One participant had SVT that correlated with palpitations by patient diary, but no episodes were sustained longer than 30 second. Results were similar in sensitivity analysis when only palpitations were considered (n=10).

Table 5. Heart Rate Parameters by Chronotropy and Exercise Capacity

Measure		Value, mean±SD	Unadjusted Difference (95%CI; p-value)	Adjusted Difference (95%CI; p value)
CPET Peak HR During Exercise, bpm	CI	117±10	-52 (-62 to -41; p<0.0001)	-48 (-56 to -39; p<0.001)
	Reduced HR	136±6	-32 (-42 to -22; p<0.0001)	-29 (-37 to -22; p<0.001)
	Normal	168±13		
CPET Peak HR, %Age Predicted Max	CI	72±5	-28% (-33 to -23; p<0.0001)	-30 (-36 to -25; p<0.001)
	Reduced HR	84±4	-16% (-21 to -11; p<0.0001)	-17 (-23 to -12; p<0.001)
	Normal	100±6		
CPET AHRR, %	CI	47±6	-53 (-61 to -45; p<0.0001)	-54 (-63 to -44; p<0.001)
	Reduced HR	66±8	-34 (-43 to -25; p<0.0001)	-35 (-43 to -26; p<0.001)
	Normal	100±11		
CPET HR Recovery at 1 minute, bpm	CI	9.1±6.1	-7.3 (-13.7 to -0.9; p=0.03)	-7.1 (-15.4 to 1.3; p=0.09)
	Reduced HR	8.1±7.5	-8.3 (-15.4 to -1.3; p=0.02)	-6.2 (-13.8 to 1.5; p=0.11)
	Normal	16.4±8		
Ambulatory Max sinus HR, bpm	CI	127±20	-32 (-49 to -15; p=0.001)	-24 (-41 to -6; p=0.01)
	Reduced HR	144±19	-14 (-32 to 3; p=0.11)	-7 (-23 to 9; p=0.39)
	Normal	159±18		
Ambulatory max HR, % Age Predicted Max	CI	81±12	-14 (-22 to -6; p=0.003)	-11 (-23 to 0.2; p=0.05)
	Reduced HR	89±15	-6 (-16 to 5; p=0.26)	-2.2 (-13 to 9; p=0.68)
	Normal	95±7		
Ambulatory AHRR, %	CI	60±24	-31 (-48 to -14; p=0.001)	-23 (-44 to -2; p=0.03)
	Reduced HR	79±27	-12 (-31 to 7; p=0.20)	-3 (-23 to 17; p=0.76)
	Normal	91±13		
Ambulatory Minimum HR, bpm	CI	58±17	14 (4 to 24, p=0.007)	8.4 (-2.1 to 19.0; p=0.11)
	Reduced HR	46±5	2 (-3 to 6; p=0.39)	0.1(-9.7 to 9.8; p = 0.99)
	Normal	44±5		
Ambulatory Average HR, bpm	CI	80±13	7.5 (-0.8 to 15.9; p=0.07)	2.3 (=7.5 to 12.2; p=0.63)
	Reduced HR	77.9±11	5.5 (-1.9 to 12.9; p=0.14)	4.0 (-5.1 to 13.1; p=0.37)
	Normal	72±5		
Ambulatory HR Variability SDNN	CI	107±40	-61 (-99 to - 22; p=0.004)	-49 (-95 to -4; p=0.03)
	Reduced HR	143±524	-24 (-61 to 13; p=0.18)	-29 (-71 to 13; p=0.16)
	Normal	168±43		

Table 5 Legend: The first row of each measure is the mean±SD for those with chronotropic incompetence ("CI", VO_2 <85%, AHRR<80%, and no alternative findings, n=9); the second row is the mean±SD for those with a reduced chronotropic response (VO_2 ≥85% and AHRR<80%, n=8) and the third row is those with peak VO_2 ≥85% and AHRR≥80% (n=16). Unadjusted and adjusted differences are compared to those with normal exercise capacity and heart rate response during exercise. Abbreviations: HR=heart rate, bpm=beats per minute, CI=chronotropic incompetence, AHRR=adjusted heart rate reserve, SDNN=standard deviation n-to-n

Supplemental Materials

Supplemental Results:

Among all participants, peak VO_2 is associated with peak heart rate during exercise with no difference in slope by the presence of cardiopulmonary symptoms (Supplemental Figure 2). To exclude the possibility that the peak heart rate is lower because participants did not reach their predicted maximum VO_2 (as opposed to the measured peak VO_2), we conducted a sensitivity analysis in which we plotted the heart rate at rest, anaerobic threshold, and peak exercise by the percentage of peak VO_2 achieved and generated models to estimate the differences in slope of heart rate to percent VO_2, using the interaction terms to estimate the difference in heart rate response (Supplemental Figure 3). The adjusted difference in peak heart rate was -14.4% among those with chronotropic incompetence accounting for differences in the percentage of predicted exercise capacity (95CI% -21 to -7.7; p= <0.001) and there was a highly statistically significant interaction between chronotropic incompetence and percent predicted peak VO_2 on peak heart rate ($p_{interaction}$<0.001). We also plotted heart rate based on the % of predicted exercise capacity they achieved and the AHRR based on the percent of achieved VO_2 (Supplemental Figure 4). Together, these findings suggest that the reduced heart rate response to exercise is not simply a manifestation that those participants did less exercise and therefore did not need to augment their heart rate as much.

Supplemental Table 1 Demographics and Medical History of Participants who Underwent Advanced Cardiopulmonary Testing (CMR and/or CPET)

Factor	Level	Persistent Cardiopulmonary Symptoms (n=19)	Recovered (n=26)	p-value
Months since Infection median (IQR)		16.9 (14.6, 17.6)	17.3 (15.8, 18.7)	
Age (years), median (IQR)		47.0 (40.0, 57.0)	56.0 (51.0, 63.0)	0.049
sex	Male	8 (42%)	18 (69%)	0.069
	Female	11 (58%)	8 (31%)	
Gender	Male	8 (42%)	17 (65%)	0.18
	Female	10 (53%)	8 (31%)	
	T (F->M)	0 (0%)	1 (4%)	
	T (M->F)	1 (5%)	0 (0%)	
Race/ Ethnicity	Hispanic/Latino	4 (22%)	5 (23%)	0.94
	White	12 (67%)	13 (59%)	
	Black/African American	1 (6%)	1 (5%)	
	Asian	1 (6%)	3 (14%)	
School completed	Grades 7-11	0 (0%)	1 (5%)	1.00
	Graduated high school/GED	3 (17%)	3 (14%)	
	Some college/Associates degree	1 (6%)	1 (5%)	
	4 years college (BS/BA)	7 (39%)	9 (41%)	
	Some/Completed graduate school	7 (39%)	8 (36%)	
Household income	<$50,000	6 (33%)	6 (24%)	0.80
	$50,001-$100,000	2 (11%)	2 (8%)	
	$100,001-200,000	3 (17%)	6 (24%)	
	>200,001	6 (33%)	7 (28%)	
	Prefer not to answer	1 (6%)	4 (16%)	
Body Mass Index (kg/m^2), mean (SD)		31.5 (7.9)	28.7 (5.8)	0.21
BMI Category	24.9 or less	4 (24%)	4 (19%)	0.17
	25 to 29.9	4 (24%)	12 (57%)	
	30 to 34.5	4 (24%)	3 (14%)	
	35 or greater	5 (29%)	2 (10%)	
Hypertension		5 (28%)	7 (28%)	1.00
Diabetes		4 (22%)	2 (8%)	0.22
Asthma/COPD		7 (39%)	3 (12%)	0.067
HIV		4 (21%)	7 (27%)	0.74
Autoimmune Disease		2 (11%)	1 (4%)	0.56
Cancer		1 (6%)	1 (5%)	1.00
Kidney Disease		0 (0%)	1 (4%)	1.00
Tobacco use		8 (44%)	6 (24%)	0.16
Hospitalized		4 (21%)	3 (12%)	0.38

Suppplemental Table 1 Legend: Fisher's Exact Test was used for categorical variables with <=5 in any cell and Peason's chi-squared test was used for categorical variables with >5 in each cell. Wilcoxon rank-sum was used for non-normally distributed continuous variables and unpaired T-test was used for normally distributed continuous variables.

Supplemental Table 2: Symptom pattern by individual symptoms

	Never had	Resolved between 1st & second visit	Developed symptoms after first visit	Persistent Symptoms
Chest pain, dyspnea, or palpitations	18	8	5	14
Chest pain	31	2	4	4
Dyspnea	22	6	3	10
Palpitations	24	4	4	7
Fatigue	18	2	8	13
Any symptom (including fatigue)	13	9	4	19

Supplemental Table 3. Echocardiographic Parameters at a median 6 months after Infection

	Symptoms (n=56)	No Symptoms (n=64)	OR (95%CI; p value)
Left Ventricular Ejection Fraction	64+-6%	64+-7%	1.12 per 5% decrease (0.81 to 1.55; p=0.49)
LV Diastolic Dysfunction	5 (9%)	4 (7%)	1.34 (0.27-6.55; p=0.72)
LV Strain	-19.6+-2.4%	-19.6+-2.7%	1.05 (0.89 to 1.24; p=0.59)
RV Dilated	2 (4%)	2 (3%)	1.96 (0.25 to 15.5; p=0.52)
RV Function Reduced	0	2 (3%)	0.48 (0.02 to 10.7; p=0.64)
RV Strain	-24.0+-4.6%	-24.0+-4.5%	1.00 (0.89-1.11; p=0.95)
Pulmonary Artery Pressure PASP>35 mm Hg (PHTN)	23.4+-4.7 0	22.6+-4.2 0	1.39 per 5 mm Hg increase (0.80 to 2.43; p=0.25)
Pericardial Effusions	4 (9%)	0	13.2 (0.7 to 260; p=0.09)

Table 3 Legend: Echocardiographic parameters by symptom status at echo visit (median 6 months). Odds ratios are adjusted for age, sex, time since SARS-CoV-2 infection, hospitalization for COVID-19; no change in sensitivity analysis additionally adjusting for medical history.

Supplemental Table 4: Rest Spirometry by Symptoms

	Symptoms (n=17)	**No Symptoms (n=22)**	**OR (95%CI; p value)**
Forced Vital Capacity, % Pred	94±17%	101±14	0.97 (0.91-1.03; p=0.31)
Forced Expiratory Volume in 1 second, % Pred	106±10	98±18	0.96 (0.90-1.03; p=0.24)
FEV1/FVC, % Pred	103±8	105±9	0.96 (0.84-1.09; p=0.49)
Slow Vital Capacity, % Pred	96±17	109±15	0.90 (0.80-1.02; p=0.10)
Inspiratory Capacity, % Pred	102±25	113±22	0.96 (0.90-1.01; p=0.12)
Expiratory Reserve Volume, % Pred	51±33	62±28	0.99 (0.95-1.03; p=0.75)
Maximum Voluntary Ventilation, % Pred	110±15	106±17	0.99 (0.94-1.04; p=0.59)

*Adjusted for age, sex, time since SARS-CoV-2 infection, hospitalization for COVID-19, BMI & Baseline Asthma/COPD

Supplemental Table 5. Differences in Peak VO_2 by Different Means of Classifying Symptoms

		Symptom Present	Symptom Absent	Unadjusted Difference	Adjusted Difference
Dyspnea, Chest Pain, or Palpitations at Visit 2 (n=17)	VO_2 (ml/kg/min)	22.1±9.3	26.0±8.2	-3.9 (-1.7 to 9.6; p=0.17)	-2.7 (-6.9 to 1.5; p=0.20)
	VO_2, % predicted	92±26	103±23	-11 (-5 to 26; p=0.18)	-11 (27 to 5, p=0.17)
Dyspnea, Chest Pain, Palpitations, or Fatigue at Visit 2 (n=23)	VO_2 (ml/kg/min)	21.2±8.2	28.8±7.7	-7.6 (-12.9 to -2.3; p=0.006)	-5.9 (-9.6 to -2.3; p=0.002)
	VO_2, % predicted	89.3±23%	111±20	-22 (-37 to -8; p=0.003)	-21 (-35 to -7; p=0.006)
Reduced Exercise Capacity at Visit 2 (n=20)	VO_2 (ml/kg/min)	23.6±9.1	24.6±8.6	-0.9 (-6.8 to 4.9; p=0.75)	-2.9 (-6.9 to 1.2; p =0.16)
	VO_2, % predicted	94±23	105±25	-11 (-27 to 4; p=0.15)	-13 (-28 to 2; p=0.09)
Persistent Symptoms vs Never Symptoms (n=12)	VO_2 (ml/kg/min)	20.1±8.6	27.3±8.8	-7.2 (-14.6 to 0.2; p=0.06)	-5.6 (-11 to 0.1; p=0.05)
	VO_2, % predicted	109±23	93±29	-17% (-39 to 5; p=0.12)	-17 (-40 to 6; p=0.14)
Symptoms at Visit 1, (n= 20)	VO_2 (ml/kg/min)	21.8±8.2	27.3±8.7	-5.5 (-11.0 to -0.03, p=0.048)	-3.0 (-7.2 to 1.0; p=0.13)
	VO_2, % predicted	93±25	103±23	-12 (-27 to +4; p=0.14)	-8.2 (-24 to 8; p=0.30)

Supplemental Table 5 Legend. N listed for the number with that symptom finding.

Supplemental Figure 1: HR, AHRR and Age Predicted Maximum HR by Chronotropic Response



Supplemental Figure 1 Legend: Results are similar whether plotting absolute HR (Top, Same as Figure 2), adjusted HRR (Middle), and APMHR (Bottom) with clear differences in the heart rate response during exercise regardless of which measure of heart rate is used.

Supplemental Figure 2: Relationship between Peak HR and VO_2 by Symptoms



Supplemental Figure 2 Legend: Scatter plot and linear fits of VO_2 by peak HR with blue dots and green line representing those without symptoms and red dots and orange line representing those with symptoms. There is a linear increase in peak VO_2 as heart rate increases, with a peak VO_2 that was 2.3ml/kg/min lower among those with symptoms accounting for heart rate (95%CI -5.6 to 1.1; p=0.18); the interaction term between symptoms and heart rate on exercise was not significant (coefficient 0.0; 95%CI -0.15 to 0.12; p=0.80). Sensitivity analysis incorporating stroke volume as measured on cardiac MRI did not significantly change the model and the coefficient for stroke volume was 0 (95%CI -0.05 to 0.20; p=0.29).

Supplemental Figure 3: HR by VO_2 and Chronotropic Incompetence



Supplemental Figure 3 Legend: Scatter plots and linear fits for (A) heart rate (beats per minute), (B) heart rate (% predicted) and (C) adjusted heart rate reserve achieved as a function of VO_2 as a percent of peak VO_2 achieved. There was an interaction between chronotropic incompetence and heart rate slope on peak heart rate, %APMHR, and AHRR. Chronotropic incompetence (CI) is defined as those with reduced exercise capacity, reduced HR response and no alterative explanation for reduced exercise capacity.

Supplemental Figure 4: Heart Rate and Adjusted Heart Rate Reserve as Percent of Predicted and Percent of Achieved VO_2



Supplemental Figure 4 Legend. On the left, heart rate is plotted on the y axis as a function of the percent of predicted VO_2 to demonstrate that the peak HR achieved and slope of the peak HR are similarly reduced among those with AHRR<80% regardless of whether they reached a peak VO_2 <85% (yellow) or >85% (teal) predicted compared to those who had normal chronotropic response to exercise (purple). This suggests that the lower achieved peak heart rate is not due to not reaching >85% of predicted exercise capacity. Secondly, on the right, AHRR is plotted as a function of the percent of achieved VO_2 (100% for all at the end of their test). Here it is clear that AHRR is the lowest among those with chronotropic incompetence (yellow), intermediate among those with a blunted heart rate response but peak VO_2 >85% (teal) and highest among those with normal exercise capacity and heart rate response (purple).

Supplemental Figure 5. Cardiac Rhythms During Button Pushes



Supplemental Figure 5 Legend: Individual participant analysis of number of button pushes and assocaited rhythm with each participant on the x axis and the number of times that individual pushed the symptom button on the y axis with each identified rhythm coded by color. Most button pushes were associated with sinus rhythm or sinus tachycardia, with supraventricular ectopy (premature atrial contractions) present among a few individuals especially the 3 with the most button pushes.